澳股詳情

本頁面由Tiger Trade Technology Pte. Ltd.提供服務

MAYNE PHARMA GROUP LTD

3.030

-0.030-0.98%

成交量：35.85萬

成交額：107.58萬

市值：2.48億

市盈率：14.60

高：3.060

開：3.000

低：2.960

收：3.060

52周最高：6.500

52周最低：2.040

股本：8,189.09萬

流通股本：6,699.72萬

量比：0.98

換手率：0.54%

股息：- -

股息率：- -

每股收益(TTM):0.208

每股收益(LYR):0.208

淨資產收益率：8.20%

總資產收益率：-1.73%

市淨率：0.63

市盈率(LYR):14.60

資料載入中...

總覽公司新聞資訊公告

概念

醫藥生物股+1.18%

資金流向

資金流入：

資金流出：

新聞資訊

Mayne Pharma集團與Italfarmaco簽署澳大利亞Blissel獨家五年許可協議

Mayne Pharma澄清：CEO未參與任何涉及自身激勵方案的薪酬決策

異動解讀 | Mayne Pharma Group盤中大漲5.58%，或因考慮股票回購計劃提振市場信心

Mayne Pharma Group持續評估資本配置策略或考慮實施市場股票回購計劃

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"Easy breezy. No more feesies.","description":"Tiger Trade is a mobile trading app offering real time data, low commission fees and a free demo account. Download now to start investing in ETFs, options and the global share market.","keywords":"老虎國際,美股交易,港股交易,交易美股,股票信息,股價,美股行情,美股打新,港股打新,IPO打新,購買美股,全球投資","social":{"ogDescription":"Tiger Trade is a mobile trading app offering real time data, low commission fees and a free demo account. Download now to start investing in ETFs, options and the global share market.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.thetigerbrokers.com/hant/stock/MYX.AU"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"NZL","license":"TBKIWI","edition":"fundamental","symbol":"MYX.AU","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"MYX.AU\",,,,,undefined,":{"symbol":"MYX.AU","market":"AU","secType":"STK","nameCN":"MAYNE PHARMA GROUP LTD","latestPrice":3.03,"timestamp":1789452720000,"preClose":3.06,"halted":0,"volume":358496,"delay":0,"changeRate":-0.009803921568627532,"nameEN":"MAYNE PHARMA GROUP LTD","floatShares":66997185,"shares":81890887,"eps":0.207588,"marketStatus":"未開盤","change":-0.03,"latestTime":"09-15 16:12:00 AEST","open":3,"high":3.06,"low":2.96,"amount":1075816,"amplitude":0.03268,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":0.207588,"tradingStatus":0,"nextMarketStatus":{"tag":"開盤","tradingStatus":0,"beginTime":1789516800000},"marketStatusCode":0,"adr":0,"exchange":"ASX","adjPreClose":3.06,"openAndCloseTimeList":[[1789430400000,1789452000000]],"volumeRatio":0.9807153911956528,"lotSize":1,"tradeCurrency":"AUD","auctionPricing":{"symbol":"MYX.AU","preClose":3.03,"auctionPrice":3.05,"auctionVolume":5066,"auctionTime":1789516438973,"referenceTime":1789468203091,"auction":1,"marketStatus":"盘前竞价","timestamp":1789516438973}},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"MYX.AU\",,,,,undefined,":{"symbol":"MYX.AU","floatShares":66997185,"roa":"-1.73%","roe":"8.20%","lyrEps":0.207588,"volumeRatio":0.9807153911956528,"shares":81890887,"dividePrice":0,"high":3.06,"amplitude":0.03268,"preClose":3.06,"low":2.96,"week52Low":2.04,"pbRate":"0.63","psRate":"0.65","week52High":6.5,"institutionHeld":0,"latestPrice":3.03,"eps":0.207588,"divideRate":0,"volume":358496,"delay":0,"ttmEps":0.207588,"open":3,"prevYearClose":3.11,"prevWeekClose":2.96,"prevMonthClose":3.1,"prevQuarterClose":2.79,"fiveDayClose":3.16,"twentyDayClose":3.23,"sixtyDayClose":2.33,"dividendPayoutRate":0.04569711225089115,"dividendGrowthYears":0,"fiveYearAvgDividendRate":0.014818181818181815},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/MYX.AU\",params:#limit:5,,,undefined,":[{"date":"2026-08-27","symbol":"MYX.AU","type":"earning","reportTimeType":"","market":"AU","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1787788800000,"name":null,"time":"","dateTimestamp":1787752800000,"actualEps":null},{"date":"2026-02-22","symbol":"MYX.AU","type":"earning","reportTimeType":"","market":"AU","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1771714800000,"name":null,"time":"","dateTimestamp":1771678800000,"actualEps":null},{"date":"2025-08-29","symbol":"MYX.AU","type":"earning","reportTimeType":"","market":"AU","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1756425600000,"name":null,"time":"","dateTimestamp":1756389600000,"actualEps":null},{"date":"2025-02-26","symbol":"MYX.AU","type":"earning","reportTimeType":"","market":"AU","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1740524400000,"name":null,"time":"","dateTimestamp":1740488400000,"actualEps":null},{"date":"2024-08-23","symbol":"MYX.AU","type":"earning","reportTimeType":"","market":"AU","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1724371200000,"name":null,"time":"","dateTimestamp":1724335200000,"actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"MYX.AU\",market:\"AU\",,,undefined,":[{"executeDate":"2023-01-18","recordDate":"2023-01-19","paymentDate":"2023-01-27","value":0.038,"currency":"AUD"}],"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"MYX.AU\",pageSize:4,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"1132428558","title":"Mayne Pharma集團與Italfarmaco簽署澳大利亞Blissel獨家五年許可協議","url":"https://stock-news.laohu8.com/highlight/detail?id=1132428558","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1132428558?lang=zh_tw&edition=fundamental","pubTime":"2026-09-15 07:52","pubTimestamp":1789429933,"startTime":"0","endTime":"0","summary":"Mayne Pharma集团宣布，已与Italfarmaco S.a签署了一项为期五年的独家许可协议。该协议针对Blissel在澳大利亚市场的推广与分销权。此举标志着Mayne Pharma在女性健康领域的战略布局进一步深化。Mayne Pharma方面表示，此次合作契合其专注于专科治疗领域的长期发展策略。通过引入Blissel这一产品，公司意在强化其在澳大利亚医疗市场中的竞争地位。而Italfarmaco则借助Mayne Pharma的本地网络，实现产品的快速渗透与市场拓展。投资者可密切关注该合作对Mayne Pharma营收结构的影响。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MYX.AU","BK7096","BK7508"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1174993621","title":"Mayne Pharma澄清：CEO未參與任何涉及自身激勵方案的薪酬決策","url":"https://stock-news.laohu8.com/highlight/detail?id=1174993621","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1174993621?lang=zh_tw&edition=fundamental","pubTime":"2026-04-30 06:25","pubTimestamp":1777501505,"startTime":"0","endTime":"0","summary":"Mayne Pharma集团今日发布声明，明确表示公司首席执行官在涉及向其本人授予激励措施的薪酬决策过程中全程回避。该制药企业强调，相关薪酬决议完全由董事会下设的薪酬委员会独立制定，确保公司治理流程符合最高标准的透明性与规范性要求。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MYX.AU","BK7508","BK7096"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1161898046","title":"異動解讀 | Mayne Pharma Group盤中大漲5.58%，或因考慮股票回購計劃提振市場信心","url":"https://stock-news.laohu8.com/highlight/detail?id=1161898046","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1161898046?lang=zh_tw&edition=fundamental","pubTime":"2026-04-29 08:17","pubTimestamp":1777421842,"startTime":"0","endTime":"0","summary":"Mayne Pharma Group Ltd（ASX: MYX）今日盘中大涨5.58%，引起了市场的广泛关注。消息面上，该公司表示正在持续评估最优资本配置方案，管理层考虑的策略选项中可能包含在公开市场回购公司股票的计划。市场分析人士指出，若实施股票回购计划，将有助于优化资本结构并提升股东价值，这提振了投资者信心。该公司强调，资本配置策略的审查工作仍在进行中，最终方案将综合考虑公司财务状况、市场环境及未来发展需求等因素。此次股价上涨反映了市场对公司潜在积极举措的乐观预期。","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["MYX.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1136228232","title":"Mayne Pharma Group持續評估資本配置策略 或考慮實施市場股票回購計劃","url":"https://stock-news.laohu8.com/highlight/detail?id=1136228232","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1136228232?lang=zh_tw&edition=fundamental","pubTime":"2026-04-29 07:37","pubTimestamp":1777419437,"startTime":"0","endTime":"0","summary":"澳大利亚制药企业Mayne Pharma Group Ltd（ASX: MYX）近日表示，公司正在持续评估最优资本配置方案。据悉，管理层考虑的策略选项中可能包含在公开市场回购公司股票的计划。\n该公司强调，资本配置策略的审查工作仍在进行中，最终方案将综合考虑公司财务状况、市场环境及未来发展需求等因素。市场分析人士指出，若实施股票回购计划，将有助于优化资本结构并提升股东价值。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7096","MYX.AU","BK7508"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":4,"totalPage":2,"pageCount":1,"totalSize":7,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/market/plate/belongs/MYX.AU\",params:#limit:6,delay:true,,,undefined,":[{"market":"AU","name":"醫藥生物股","id":"package_au_concept_yyswg","bkCode":"BK7508","changeRate":0.011805}]}}